新型多靶点抗VEGF融合蛋白Conbercept治疗湿性年龄相关性黄斑变性的临床研究

Clinical study of a novel multi-target anti-VEGF fusion protein Conbercept in the treatment of wet age-related macular degeneration

目的:探讨新型多靶点抗血管内皮生长因子(VEGF)融合蛋白Conbercept治疗湿性年龄相关性黄斑变性(w-AMD)的临床效果。方法:100例单眼w-AMD患者,均接受玻璃体腔注射抗VEGF药物治疗并随访6个月。根据注射药物不同将患者分为Conbercept(康柏西普)组和Lucentis(雷珠单抗)组,每组各50例。比较两组治疗前后最佳矫正视力(BCVA)、中心视网膜厚度(CRT)和脉络膜新生血管(CNV)面积变化及医疗费用,记录相关不良反应发生情况。结果:治疗后3d、1周、半个月、1个月、3个月、6个月,两组患者BCVA较治疗前逐渐提高,CRT、CNV面积逐渐下降,差异均有统计学意义(P<0.05);两组BCVA、CRT和CNV面积比较,差异均无统计学意义(P>0.05)。按每只患眼注射6次计算,Conbercept组比Lucentis组共节省90万元,平均每只患眼节省1.8万元。两组患者术后均未出现视网膜脱离、眼内炎等并发症,不良反应率比较,差异无统计学意义(P>0.05)。结论:国产新型抗VEGF药物融合Conbercept治疗w-AMD可取得同Lucentis接近的临床效果,安全性好,且医疗费用相对低廉,值得推广应用。

Objective:To investigate the clinical effect of a novel multi-target anti-vascular endothelial growth factor vascular endothelial growth factor(VEGF)fusion protein Conbercept in the treatment of wet age-related macular degeneration(w-AMD).Methods:A total of 100 patients with monocular w-AMD were treated with intravitreal injection of anti-vascular drugs and followed up for 6 months.100 patients with w-AMD were divided into Conbercept group and Lucentis group according to the different injection drugs,with 50 cases in each group.The changes of best corrected visual acuity(BCVA),central retinal thickness(CRT),choroidal neovascularization(CNV)area and medical expenses before and after treatment were compared between the two groups,and the occurrence of related adverse reactions was recorded.Results:BCVA in Conbercept group and Lucentis group increased gradually after 3 days,1 week,15 days,1 month,3 months and 6 months of treatment,and the area of CRT and CNV decreased gradually(P<0.05).There was no significant difference in the area of BCVA,CRT and CNV between the two groups(P>0.05).According to 6 injections per eye,the area of BCVA in Conbercept group was higher than that of Lucenti group(P>0.05).There were no complications such as retinal detachment and endophthalmitis in the two groups,and there was no significant difference in the rate of adverse reactions(P>0.05).Conclusion:Conbercept is a new domestic anti-VEGF drug,which has a similar clinical effect to Lucentis in the treatment of w-AMD with good safety and relatively low medical cost,which is worthy of vigorous promotion and application.